Hi, I am Harsha Rajasimha, Founder and Chairman of IndoUSrare, an independent non-profit organization focused on helping patients with rare diseases of Indian origin in the USA, India and globally with a vision to build collaborative bridges between the east and the west to accelerate research and development of diagnostics and therapies through education, advocacy, research & grants.
WASHINGTON – The National Capital Consortium for Pediatric Device Innovation (NCC-PDI), in collaboration with MedTech Innovator, is now accepting applications for its showcase pitch event on March 23, 2020, in College Park, Maryland. The competition is focused on pediatric devices in three areas of critical need: cardiovascular, orthopedic and spine, and neonatal intensive care unit (NICU).
Up to ten companies selected from this event will move on to the “Make Your Medical Device Pitch for Kids!” on Oct. 4, 2020 in Toronto, Canada, to compete for up to $250,000 in grant awards. These companies also receive a spot in the MedTech Innovator 2020 Accelerator – Pediatric Track, which provides a customized curriculum and in-depth mentorship.
BioMarker Strategies, LLC, today announced that the National Cancer Institute (NCI) has awarded the Company a Phase II Small Business Innovation Research (SBIR) contract to continue development of its PathMAP® Immunotherapy test to predict clinical response to PD-1/PD-L1 targeted immune checkpoint inhibitors, both alone and in combination with chemotherapies, for individual patients with non-small cell lung cancer (NSCLC). The contract totals $1.5 million over two years.
Image: https://finance.yahoo.com
A company developing treatments for drug-resistant bacterial infections is getting a boost from the Department of Defense.
Gaithersburg, Maryland-based Adaptive Phage Therapeutics, also known as APT, said Tuesday that it the DoD had awarded it $10.2 million to fund a clinical trial to develop its personalized bacteriophage therapeutic, PhageBank.
CHICAGO/TEL AVIV-YAFO (January 7, 2020) – LionBird has a new partner: Robert Lord. Lord is the co-founder of Protenus, a healthcare compliance analytics company from LionBird’s second fund. Lord joins LionBird to provide strategic insight as the company prepares to hone its digital health focus for its upcoming fund, LionBird III. In addition to his role at LionBird, Lord is the Chairman of the Board of Protenus, providing support to the Protenus team while also completing his medical degree at Johns Hopkins University School of Medicine.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched* no earlier than mid-2018.
To come up with this list, BioSpace sorted companies into that age grouping, and they were then weighted by a number of different categories and finally ranked in a cumulative fashion, based on the points awarded for each category. These categories were: Finance, Collaborations, Pipeline and Innovation (view methodology below).
Image: https://www.biospace.com
Here we are… 2020. As we approach this new decade with a fresh lens of excitement and rejuvenated ambition for impact, there are a few fundamentals that we should review. Elements we all know are important in our commercial strategy, yet can be abandoned in the hustle of launching a new product, service, or company to market. We should take a moment to reflect on the past decade’s success and challenges specific to the life science industry. Many questions still remain as we progress into the new year—will painful blood draws finally be a thing of the past thanks to Velano Vascular’s needless vascular access device? Or, could cutting edge digital health companies, such as Livongo or Virta Health, eliminate chronic conditions like Type 2 diabetes? Further, many often wonder, will traditional pharmaceutical drugs be replaced by Prescription Digital Therapies (PDT) altogether?
Oncology, neurology, and fatty liver disease are among the areas where one can expect to see significant activity this year, according to forecasts from investment bank analysts.
Anticipated highlights for 2020 include potentially the first regulatory approval of a drug to treat the liver disease nonalcoholic steatohepatitis, or NASH; the launches of two new drugs for sickle cell disease; and late-stage data for a drug to treat amyotrophic lateral sclerosis, among others. Several company executives also shared their insights in a story published over the weekend.
Competition for startups aims to increase the pace of development and commercialization of critically needed pediatric medical devices. In the world of innovation, devices used for pediatric medical care, particularly the very young, are lagging behind those created for adult purposes. A contest is now open, inviting innovators to do something about it. Top contenders will be awarded with support from an innovation accelerator to further develop their device and an opportunity to win up to $250,000 in grant money.
A new initiative spearheaded by Johns Hopkins is setting out to organize and grow the digital health community in the region, with an aim of fueling successful startups.
The Chesapeake Digital Health Exchange (Chesapeake DHX) wants to create more connectivity between the stakeholders in digital health, such as companies, investors and healthcare providers. The regional effort aims to include Maryland, D.C. and Northern Virginia.
